Antiviral composition

Abstract

To provide an antiviral composition that exhibits superior antiviral effect.SOLUTION: An antiviral composition contains a surfactant. The surfactant does not have an ionic hydrophilic group, while having at least one hydrophobic group with seven or more carbon atoms. Alternatively, the surfactant has either a single ionic hydrophilic group or ionic hydrophilic groups with different charges, while having at least one hydrophobic group with 11 or more carbon atoms or at least two hydrophobic groups with nine or more carbon atoms.SELECTED DRAWING: None

Description

[Technical Field]

[0001] The present invention relates to antiviral compositions. [Background technology]

[0002] Some viruses can infect humans, and virus inactivators have traditionally been used to prevent infection.

[0003] Since the outbreak of the novel coronavirus disease (COVID-19) in 2020 has increased demand for virus inactivators, various studies have been conducted to increase the variety of compositions suitable for virus inactivation applications. For example, at the request of the Ministry of Economy, Trade and Industry, the National Institute of Technology and Evaluation (NITE) is evaluating the effectiveness of various surfactants in order to respond to the spread of the new coronavirus infection and increase the options for disinfection methods other than alcohol at home and in the workplace (see Non-Patent Document 1).

[0004] In addition, with the outbreak of COVID-19, in order to prevent droplet infection, stores such as supermarkets, department stores, restaurants, accommodation facilities, medical facilities, and offices are increasingly installing acrylic panels and vinyl curtains at cash registers, reception counters, interview counters, and windows, and are also increasingly installing acrylic partitions on tables such as counter seats in restaurants and desks in offices. [Prior art documents] [Non-patent literature]

[0005] [Non-Patent Document 1] “Results of the validation test for the evaluation of the effectiveness of alternative disinfectant candidates using influenza viruses, April 30, 2020, National Institute of Technology and Evaluation,” [online], announced May 1, 2020, National Institute of Technology and Evaluation, Internet<URL:https: / / www.nite.go.jp / data / 000108456.pdf> Summary of the Invention [Problem to be solved by the invention]

[0006] Under the circumstances described above, there is a need for a composition that can impart antiviral properties to the surface of an article, such as a hard surface or a plastic surface, or to the surface of the body.

[0007] The present invention has been made in view of the above-mentioned current situation, and an object of the present invention is to provide an antiviral composition that exhibits excellent antiviral effect. [Means for solving the problem]

[0008] That is, present invention (1) is an antiviral composition comprising a surfactant, wherein the surfactant has no ionic hydrophilic group and at least one hydrophobic group having 7 or more carbon atoms, or has only one ionic hydrophilic group or has ionic hydrophilic groups with opposite charges, and has at least one hydrophobic group having 11 or more carbon atoms or at least two hydrophobic groups having 9 or more carbon atoms.

[0009] As used herein, "antiviral" refers to an effect confirmed by a test method in which a composition is applied to the surface or fabric of an article such as a plastic plate or the body, dried, and then a virus solution is dropped onto the surface or fabric to extract viruses from the surface or fabric, and the virus infectivity is measured, as shown in the examples described below. Standard test methods are specified in ISO 21702 and JIS 1922:2016. The antiviral composition of the present invention can impart excellent antiviral properties to the surface of an article or the body in advance when used on the surface of an article or the body. In other words, by forming a coating film on the surface of the object in advance, the composition is an agent that can inactivate viruses even if they later adhere to the object, and can be referred to as an "antiviral agent" or an "antiviral coating agent." On the other hand, "virus inactivation" refers to the effect confirmed by a suspension test as shown below. This test method involves adding a virus solution to a liquid composition and measuring the virus infectivity after a certain period of time. It is specified as a standard test method in ASTM 1052. A virus inactivator is an agent that can immediately inactivate viruses by coming into contact with viruses already present on the surface of an object or in a liquid. Note that Non-Patent Document 1 above essentially evaluated the "virus inactivation" effect, not the "antiviral" effect. The antiviral composition and the virus inactivator differ in that the antiviral composition inactivates viruses in a dry state, while the virus inactivator inactivates viruses in a solution state. The antiviral composition of the present invention is a composition that can impart the above-described antiviral properties to the surface of an article or the surface of the body against at least one type of virus. The antiviral composition of the present invention may also be used for virus inactivation.

[0010] In the antiviral composition of the present invention, one surfactant can exert an excellent antiviral effect. The reasons why it can exert such an excellent antiviral effect are thought to be as follows. It is important that the hydrophobic group of the nonionic surfactant has seven or more carbon atoms, and it is thought that the hydrophobic group of the nonionic surfactant denatures and destroys the envelope membrane of enveloped viruses such as influenza viruses, thereby inactivating the viruses. Secondly, because the hydrophilic group of the nonionic surfactant is not charged, it is thought that it can be efficiently oriented (aligned) on hard and soft surfaces, which increases the contact efficiency between the virus and the surfactant and makes it easier to exert its antiviral effect. However, the charge state of the hydrophilic group of a surfactant has a smaller effect on the antiviral effect than the number of carbon atoms in the hydrophobic group; therefore, as long as the hydrophobic group has 11 or more carbon atoms, or the two hydrophobic groups have 9 or more carbon atoms, a surfactant having only one ionic hydrophilic group, or a surfactant having two ionic hydrophilic groups with different charges, can exhibit an effective antiviral effect. As long as the surfactant according to the present invention has the above-described configuration, it can be at least one surfactant selected from the group consisting of nonionic surfactants, anionic surfactants, cationic surfactants, and amphoteric surfactants. Any of these surfactants will exhibit an effective antiviral effect, but nonionic surfactants, cationic surfactants, and amphoteric surfactants are preferred.

[0011] In this specification, the term "ionic hydrophilic group" may be any hydrophilic group that exhibits ionic properties or can exhibit ionic properties and that is contained in general cationic surfactants, anionic surfactants, and amphoteric surfactants. Examples of such groups include cationic groups such as a quaternary ammonium group, anionic groups such as a carboxylic acid (salt) group, a sulfonic acid (salt) group, a sulfuric acid (salt) group, a phosphonic acid (salt) group, and a phosphoric acid (salt) group, and zwitterionic groups such as an amine oxide group.

[0012] The antiviral composition of the present invention contains a surfactant having at least one hydrophobic group having 7 or more carbon atoms and no ionic hydrophilic group, and / or a surfactant having at least one hydrophobic group having 11 or more carbon atoms or at least two hydrophobic groups having 9 or more carbon atoms and either only one ionic hydrophilic group or two ionic hydrophilic groups with opposite charges, thereby enabling the composition to exhibit an excellent antiviral effect.

[0013] In the antiviral composition of the present invention, the hydrophobic group may be a hydrocarbon group, a hydroxyalkyl group, a hydroxyaryl group, a halogenated alkyl group, a halogenated aryl group, a (poly)alkylene oxide group, or a group formed by combining two or more of these groups, with a hydrocarbon group being preferred. That is, the present invention (2) is the antiviral composition of the present invention (1), in which the hydrophobic group is a hydrocarbon group. Furthermore, in the antiviral composition of the present invention, the surfactant preferably has no ionic hydrophilic group or only one ionic hydrophilic group. That is, the surfactant preferably has no ionic hydrophilic group or only one anionic group such as a cationic group such as a quaternary ammonium group, a carboxylic acid (salt) group, a sulfonic acid (salt) group, a sulfate (salt) group, a phosphonic acid (salt) group, or a phosphate (salt) group, or a zwitterionic group such as an amine oxide group. The term "carboxylic acid (salt) group" refers to a carboxylic acid group and / or a carboxylate salt group. The same applies to sulfonic acid (salt) group, sulfuric acid (salt) group, phosphonic acid (salt) group, and phosphoric acid (salt) group. By using such a surfactant, the antiviral effect of the antiviral composition of the present invention can be made even more excellent.

[0014] The present invention (3) is the antiviral composition of the present invention (1) or (2) for use on hard surfaces. The present invention (4) is an antiviral composition used on a plastic surface in combination with any one of the present inventions (1) to (3). "Using the antiviral composition of the present invention on a hard surface or a plastic surface" means that the antiviral composition of the present invention is sprayed or applied to the surface, thereby imparting antiviral properties to the surface.

[0015] The present invention (5) is an antiviral coating agent characterized by containing the antiviral composition of any one of the present inventions (1) to (4). The antiviral coating agent of the present invention can impart antiviral properties to the surface of an article or the surface of the body by coating the surface of the article or the surface of the body. The coating may be any method capable of forming a film, but is preferably a method using a paint application.

[0016] The present invention (6) is the antiviral coating agent of the present invention (5) used for coating human skin. By coating the surface of a person's body, such as a finger, with the antiviral composition of the present invention, antiviral properties can be imparted to the human skin surface. The coating is preferably achieved by application.

[0017] The present invention (7) is a sanitary material characterized by comprising the antiviral composition of any one of the present inventions (1) to (4) or the antiviral coating agent of the present invention (5) or (6). The sanitary material of the present invention contains the antiviral composition of the present invention or the antiviral coating agent of the present invention, and therefore, by using the sanitary material of the present invention, it is possible to impart antiviral properties to the surface of an article or the surface of the body.

[0018] The present invention also relates to an antiviral composition containing a surfactant having at least one hydrophobic group having 11 or more carbon atoms or at least two hydrophobic groups having 9 or more carbon atoms, wherein the surfactant has no ionic hydrophilic group, only one ionic hydrophilic group, or two ionic hydrophilic groups with opposite charges. [Effects of the Invention]

[0019] The antiviral composition of the present invention exhibits excellent antiviral effects. DETAILED DESCRIPTION OF THE INVENTION

[0020] The antiviral composition of the present invention will be described below with reference to specific embodiments. However, the present invention is not limited to the following embodiments and can be appropriately modified and applied within the scope of the present invention.

[0021] The antiviral composition of the present invention is characterized by comprising a surfactant having at least one hydrophobic group having 7 or more carbon atoms and no ionic hydrophilic group, and / or a surfactant having at least one hydrophobic group having 11 or more carbon atoms or at least two hydrophobic groups having 9 or more carbon atoms and either only one ionic hydrophilic group or two ionic hydrophilic groups with different charges. Each component of the antiviral composition of the present invention will be described below.

[0022] A surfactant according to the present invention that does not have an ionic hydrophilic group has at least one hydrophobic group having 7 or more carbon atoms. A surfactant according to the present invention that has only one ionic hydrophilic group or has ionic hydrophilic groups with different charges has at least one hydrophobic group having 11 or more carbon atoms or at least two hydrophobic groups having 9 or more carbon atoms. The "hydrophobic group" includes a hydrocarbon group, a (poly)alkylene oxide group, or a group formed by bonding two or more of these groups, and may further contain a hydroxyl group or a halogen atom, but a hydrocarbon group is preferred. The (poly)alkylene oxide group refers to an alkylene oxide group or a polyalkylene oxide group. The (poly)alkylene oxide group is preferably, for example, a (poly)ethylene oxide group. The valence of the hydrophobic group is not particularly limited, and may be, for example, monovalent, divalent, trivalent or higher. Examples of the hydrocarbon group include saturated aliphatic hydrocarbon groups, unsaturated aliphatic hydrocarbon groups, aromatic hydrocarbon groups, and groups formed by combining two or more of these groups, with saturated aliphatic hydrocarbon groups (alkyl groups) being preferred. In the surfactant having only one ionic hydrophilic group or having ionic hydrophilic groups with different charges, the hydrophobic group having 9 or more carbon atoms preferably has 10 or more carbon atoms. The upper limit of the number of carbon atoms in the hydrophobic group is not particularly limited, but is, for example, 36 or less, preferably 24 or less, and more preferably 18 or less.

[0023] The surfactant contained in the antiviral composition of the present invention further has either no ionic hydrophilic group, only one ionic hydrophilic group, or two ionic hydrophilic groups with different charges. The surfactant not having an ionic hydrophilic group means that the surfactant is a general nonionic surfactant. The surfactant having only one ionic hydrophilic group means that the surfactant has one cationic group such as a quaternary ammonium group, one anionic group such as a carboxylic acid (salt) group, a sulfonic acid (salt) group, a sulfuric acid (salt) group, a phosphonic acid (salt) group, or a phosphoric acid (salt) group, or one zwitterionic group such as an amine oxide group. The surfactant having ionic hydrophilic groups with different charges means that the surfactant has one or more cationic groups and one or more anionic groups, and the number of cationic groups and the number of anionic groups may be the same or different. Among these, it is preferable that the surfactant has two ionic hydrophilic groups (total) with different charges. That is, it is preferable that the surfactant has one cationic group and one anionic group.

[0024] As described above, the surfactant contained in the antiviral composition of the present invention can be at least one surfactant selected from the group consisting of nonionic surfactants, anionic surfactants, cationic surfactants, and amphoteric surfactants, as long as it has the above-mentioned configuration. Any surfactant will exhibit an effective antiviral effect, but nonionic surfactants, cationic surfactants, and amphoteric surfactants are particularly preferred.

[0025] In one preferred embodiment of the present invention, the surfactant contained in the antiviral composition of the present invention is at least two surfactants selected from the group consisting of a nonionic surfactant, a cationic surfactant, and an amphoteric surfactant, all of which have the above-mentioned configuration. For example, a combination of a nonionic surfactant and a cationic surfactant, a combination of a nonionic surfactant and an amphoteric surfactant, or a combination of a cationic surfactant and an amphoteric surfactant is preferred.

[0026] (cationic surfactant) The surfactant contained in the antiviral composition of the present invention may be a cationic surfactant. The cationic surfactant is preferably, for example, a compound having a quaternary ammonium cation (quaternary ammonium compound), and more preferably has a cation represented by the following general formula (1). [ka]

[0027] [In formula (1), R 1 ~R 4 represents a hydrophobic group. 1 has 11 or more carbon atoms, or R 1 , R 2 Each of these has 9 or more carbon atoms. 1 ~R 3 If the compound is double-bonded to either R 4 R does not have to exist. 1 ~R 4 Any two of them may be bonded to each other to form a ring (for example, an aromatic ring). Above R 1 ~R 4 The preferred type of R 1 , R 2 The preferred number of carbon atoms is the same as the preferred type and preferred number of carbon atoms of the hydrophobic group described above. Also R 1 If the number of carbon atoms is 11 or more, R 2Although the number of carbon atoms of is not particularly limited, for example, it is preferably a hydrocarbon group having 1 to 7 carbon atoms (such as a methyl group or a benzyl group), a hydroxyethyl group, or a (poly)ethylene oxide group. R 3 , R 4 The number of carbon atoms in the alkyl group is not particularly limited, but is preferably 1 to 5, and more preferably 1 or 2, for example.

[0028] The cationic surfactant may be in the form of any salt, and suitable examples include chlorides, bromides, cetyl phosphates, propionates, methyl sulfates, adipates, carbonates, and hydrogen carbonates.

[0029] The cationic surfactant can exert an antiviral effect by contacting the virus with the surfactant. Furthermore, cationic surfactants exhibit bactericidal effects even in small amounts, and it is believed that the antiviral composition of the present invention can also exhibit excellent bactericidal effects.

[0030] In the antiviral composition of the present invention, the cationic surfactant is preferably a tetraalkylammonium salt, a dialkylmethylpolyoxyethylammonium salt, an alkylbenzyldimethylammonium salt, a cetylpyridinium salt, an alkyldimethylhydroxyethylammonium salt, or the like, which satisfies the above-mentioned requirement for the number of carbon atoms. The antiviral composition of the present invention may contain one or more of these quaternary ammonium compounds.

[0031] (Amphoteric surfactant) The surfactant contained in the antiviral composition of the present invention may be an amphoteric surfactant. Examples of amphoteric surfactants include laurylaminopropionic acid (salts), alkyl betaines, alkylamino betaines, alkylamido betaines, alkylamidopropyl betaines, alkylhydroxysulfobetaines, alkylamine oxides, alkylamidoamine oxides, alkyldiaminoethylglycine (salts), etc., which satisfy the above-mentioned carbon number requirements. Among these, laurylaminopropionic acid (salts), alkyl betaines, alkylamine oxides, and alkyldiaminoethylglycine (salts) are preferred, and laurylaminopropionic acid (salts), alkylamine oxides, and alkyldiaminoethylglycine (salts) are more preferred. Examples of the salt include metal salts such as alkali metal salts, ammonium salts, and organic amine salts.

[0032] (nonionic surfactant) The surfactant contained in the antiviral composition of the present invention may be a nonionic surfactant. Examples of nonionic surfactants include polyoxyalkylene alkyl ethers, polyoxyalkylene alkylphenyl ethers, fatty acid alkanolamides, polyoxyalkylene fatty acid alkanolamides, polyoxyalkylene fatty acid esters, polyoxyalkylene sorbitan fatty acid esters, glycerin fatty acid esters, polyglycerin fatty acid esters, sorbitan fatty acid esters, sucrose fatty acid esters, alkyl (poly)glucosides, polyoxyalkylene methyl ether fatty acid esters, propylene glycol fatty acid esters, polyoxyalkylene alkylamines, fatty acid diethanolamides, and Quillaja saponin, which satisfy the above-mentioned carbon number requirements. Among these, polyoxyalkylene alkyl ethers and alkyl (poly)glucosides are preferred. The oxyalkylene group is preferably an oxyethylene group and / or an oxypropylene group, and the number of repeating groups is preferably 2 to 20, more preferably 5 to 10. The alkyl (poly)glucoside refers to alkyl glucoside and / or alkyl polyglucoside.

[0033] (anionic surfactant) The surfactant contained in the antiviral composition of the present invention may be an anionic surfactant. Examples of anionic surfactants include fatty acids (salts), alkyl ether carboxylates, alkanesulfonates, α-olefin sulfonates, α-sulfofatty acid ester salts, alkylbenzenesulfonates, alkyl succinates, alkyl sulfates, alkyl sulfate ester salts, alkyl ether sulfate ester salts, polyoxyalkylene alkyl ether acetates, polyoxyalkylene alkyl ether sulfate ester salts, etc., which satisfy the above-mentioned carbon number requirements. Preferred examples of anionic surfactants include polyoxyalkylene alkyl ether acetates, polyoxyalkylene alkyl ether sulfate ester salts, and fatty acids (salts). Examples of the salt include metal salts such as alkali metal salts, ammonium salts, and organic amine salts.

[0034] The preferred number of carbon atoms in the hydrophobic group of the surfactant is the same as the preferred number of carbon atoms in the hydrophobic group described above.

[0035] In the antiviral composition of the present invention, the surfactant may be selected from the group consisting of dialkyldimethylammonium salts (all alkyl groups have 9 or more carbon atoms), alkyldimethylhydroxyethylammonium salts (alkyl groups have 11 or more carbon atoms), benzalkonium salts (alkyl groups have 11 or more carbon atoms), alkylaminopropionates (alkyl groups have 11 or more carbon atoms), alkyldimethylamine oxides (alkyl groups have 11 or more carbon atoms), alkyldiethylamine oxides (alkyl groups have 11 or more carbon atoms), alkyldimethylbetaines (alkyl groups have 11 or more carbon atoms), alkyldiaminoethylglycine salts (alkyl groups have 11 or more carbon atoms), alkylglucosides (alkyl groups have and at least one surfactant selected from the group consisting of: fatty acid alkanolamides (the alkyl or alkenyl group derived from a fatty acid has 7 or more carbon atoms), fatty acid alkanolamides (the alkyl group has 7 or more carbon atoms), polyoxyethylene alkyl ethers (the alkyl group has 7 or more carbon atoms), polyglycerin monofatty acid esters (the alkyl or alkenyl group derived from a fatty acid has 7 or more carbon atoms), diglycerin monofatty acid esters (the alkyl or alkenyl group derived from a fatty acid has 7 or more carbon atoms), propylene glycol monofatty acid esters (the alkyl or alkenyl group derived from a fatty acid has 7 or more carbon atoms), and polyoxyethylene polyoxypropylene alkyl ethers (the alkyl group has 7 or more carbon atoms). The salt is not particularly limited, but the salts mentioned above can be suitably used.

[0036] In the antiviral composition of the present invention, the concentration of the surfactant is preferably 0.005% by mass or more, more preferably 0.01% by mass or more, even more preferably 0.05% by mass or more, and particularly preferably 0.1% by mass or more. When the concentration of the surfactant is equal to or higher than the predetermined concentration, the antiviral effect of the antiviral composition of the present invention can be made even better. In addition, the concentration of the surfactant in the antiviral composition of the present invention is preferably 10% by mass or less, more preferably 5% by mass or less, even more preferably 2% by mass or less, still more preferably 1% by mass or less, still more preferably 0.5% by mass or less, and particularly preferably 0.2% by mass or less. When the concentration of the surfactant is equal to or less than the predetermined concentration, the solution can be economical. The above-mentioned surfactant concentration is the total concentration of surfactants that satisfy the predetermined conditions and that are contained in the antiviral composition of the present invention, calculated as a pure content. Such a low total surfactant concentration makes it difficult for wipe marks to remain on the surface of the object to which it is applied, and also provides excellent antiviral effects.

[0037] (Other ingredients) The antiviral composition of the present invention may contain, in addition to the surfactant of the present invention described above, other surfactants, chelating agents, solvents, acidic agents, alkaline agents, solubilizing agents, viscosity modifiers, corrosion inhibitors, dispersants, antifoaming agents, fluorescent brightening agents, fragrances, coloring powders, stabilizers, enzymes, and the like.

[0038] The antiviral composition of the present invention may contain surfactants other than the surfactant of the present invention described above, but the content thereof is preferably 1% by mass or less, and more preferably 0.1% by mass or less, relative to 100% by mass of the antiviral composition. It is further preferable that the antiviral composition of the present invention is substantially free of surfactants other than the surfactant of the present invention described above.

[0039] The antiviral composition of the present invention may contain a chelating agent such as an aminocarboxylic acid chelating agent, a phosphonic acid chelating agent, a phosphoric acid chelating agent, or an ether carboxylate chelating agent. The mass concentration (total mass concentration) of the chelating agent in the antiviral composition of the present invention is preferably 0 to 10 mass%, more preferably 0 to 6 mass%, and even more preferably 0 to 2 mass%.

[0040] The antiviral composition of the present invention may or may not contain a lower alcohol; however, from the viewpoint of bactericidal effect and virus inactivation effect, it is preferable that the concentration of the lower alcohol in the antiviral composition of the present invention is 50% by mass or more. When the concentration of the lower alcohol is 50% by mass or more, the bactericidal effect and virus inactivation effect are enhanced, and while excellent antiviral properties can be exhibited, the virus inactivation effect can also be made very excellent, increasing the possibility of adequately preventing infectious diseases and food poisoning. In this specification, the lower alcohol refers to an alcohol having 5 or less carbon atoms. The valence of the alcohol is not particularly limited. When a plurality of types of lower alcohols are used, the concentration of the lower alcohol is the total concentration of the plurality of types of lower alcohols.

[0041] From the viewpoint of optimally exerting the bactericidal effect and virus inactivation effect, the concentration of the lower alcohol is more preferably 60% by mass or more, and even more preferably 65% ​​by mass or more and 75% by mass or less.

[0042] Furthermore, from the viewpoint of optimally exerting the bactericidal effect and virus inactivating effect, the concentration of alcohols, including lower alcohols and higher alcohols, in the antiviral composition of the present invention is preferably 50% by mass or more. In this specification, higher alcohol refers to an alcohol having 6 or more carbon atoms. The valence of the alcohol is not particularly limited. The concentration of the alcohol is more preferably 60% by mass or more, and even more preferably 65% ​​by mass or more and 75% by mass or less. The antiviral composition of the present invention can exhibit excellent antiviral effects even when it contains a low concentration of a lower alcohol or a higher alcohol or does not contain any lower alcohol or higher alcohol.

[0043] (water) The antiviral composition of the present invention preferably further contains water. Water is blended as the balance other than the other components, and its content is not particularly limited. The water is not particularly limited, but examples thereof include tap water, distilled water, purified water, pure water, ion-exchanged water, etc., and one or more of these may be used. In the virus inactivating agent of the present invention, the mass concentration of water is preferably 1.00 to 99.995 mass%, more preferably 3.00 to 99.99 mass%, even more preferably 5.00 to 99.9 mass%, still more preferably 7.00 to 99.8 mass%, still more preferably 10.00 to 50.00 mass%, particularly preferably 15.00 to 40.00 mass%, and most preferably 20.00 to 35.00 mass%. In the antiviral composition of the present invention, the mass ratio of water to the surfactant according to the present invention (water:surfactant) is, for example, preferably 4:1 to 2000:1, more preferably 10:1 to 1000:1, and even more preferably 40:1 to 500:1. The antiviral composition of the present invention may be substantially composed of the surfactant of the present invention and water, and the content of other components other than the surfactant of the present invention, alcohol, and water is preferably 10% by mass or less, more preferably 1% by mass or less, and even more preferably 0.1% by mass or less. It is particularly preferable that the antiviral composition of the present invention is substantially free of other components other than the surfactant of the present invention, alcohol, and water.

[0044] (pH) The pH of the antiviral composition of the present invention is preferably 3.0 to 11.0, more preferably 4.0 to 10.0, and even more preferably 5.0 to 10.0. The pH can be adjusted by controlling the amount of an acidic agent such as sulfuric acid, hydrochloric acid, sulfamic acid, malic acid, citric acid, lactic acid, tartaric acid, or gluconic acid, or an alkaline agent such as sodium hydroxide, potassium hydroxide, an amine compound, a silicate, a carbonate, or a hydrogen carbonate. pH is measured at 25°C using a pH meter.

[0045] (Application) Next, the uses of the antiviral composition of the present invention will be described. The antiviral composition of the present invention can be used on the surfaces of hard materials, soft materials, and body surfaces. Examples of hard materials include metals, ceramics, plastics, glass, and surface-treated wood. Examples of soft materials include fibers. Examples of body surfaces include the human body (e.g., fingers).

[0046] As described above, the antiviral composition of the present invention is preferably used on the surface of a hard material, for example. The antiviral composition of the present invention is preferably used on, for example, a metal surface, a plastic surface, or a fiber surface. Furthermore, the antiviral composition of the present invention is preferably used on human skin, for example.

[0047] The antiviral composition of the present invention may also be used in an antiviral coating agent. The antiviral coating agent of the present invention can impart antiviral properties to the surface of an article or the surface of the body by coating the surface of the article or the surface of the body. By using such an antiviral coating agent, viral infection can be sufficiently prevented.

[0048] The antiviral composition of the present invention may also be used in hygiene materials. The antiviral composition of the present invention exhibits excellent antiviral effects, and therefore, by using sanitary materials containing such an antiviral composition, viral infection can be sufficiently prevented.

[0049] Hygiene supplies are not particularly limited, but examples include masks, disposable gloves, disposable dishcloths, tissue paper, wet tissues, etc.

[0050] The antiviral composition of the present invention may be added to hand washing liquid, neutral detergent, or deodorant. The antiviral composition of the present invention, and hand washing liquids, neutral detergents, deodorants, and the like containing the antiviral composition of the present invention may be packed in pump bottles or spray bottles.

[0051] The antiviral composition of the present invention exhibits excellent antiviral effects. Furthermore, when the antiviral composition of the present invention has a low lower alcohol concentration (for example, less than 40% by mass), the object of use is less likely to deteriorate when the object is plastic or the like. Naturally, the object of use is also less likely to deteriorate when the object of use is metal or fiber. Furthermore, even when the antiviral composition comes into contact with human skin, it is less likely to cause damage to the skin. When the lower alcohol concentration is high (for example, 50% by mass or more), the bactericidal effect and virus inactivation effect are suitably exhibited, and it is effective in reducing the risk of infectious diseases and food poisoning.

[0052] The present invention is also a method of using the antiviral composition of the present invention. The method of use of the present invention may involve diluting the antiviral composition of the present invention with water, etc. For example, the surfactant concentration during use of the antiviral composition of the present invention is preferably 1% by mass or less, more preferably 0.5% by mass or less, even more preferably 0.25% by mass or less, and particularly preferably 0.1% by mass or less. [Example]

[0053] The following examples will explain the present invention in more detail, but the present invention is not limited to these examples. In the examples, "%" means "% by mass" unless otherwise specified.

[0054] (Examples 1 to 53) and (Comparative Examples 1 to 4) Antiviral compositions according to Examples 1 to 53 and Comparative Examples 1 to 4 were prepared according to the formulations shown in Tables 1 to 7. The results of the performance evaluations are shown in Tables 1 to 8. In addition, the manufacturers of the compounds in Tables 1 to 7 are as follows:

[0055] <Cationic surfactants (quaternary ammonium compounds)> Didecyldimethylammonium methosulfate: Lipocard 210-80MSPG (Lion Specialty Chemicals Co., Ltd.) (Contains two alkyl groups with 10 carbon atoms and one ammonium group, which is an ionic hydrophilic group.) Dimethyldioctylammonium chloride: Bardac LF80 manufactured by Lonza Japan Co., Ltd. (has one ammonium group, which is an ionic hydrophilic group, but does not have any hydrophobic groups with 9 or more carbon atoms) Alkyldimethylhydroxyethylammonium chloride: Prepagen HY manufactured by Clariant Japan Co., Ltd. (a mixture containing one alkyl group having 12 to 14 carbon atoms and one ammonium group, which is an ionic hydrophilic group.) Benzalkonium chloride: Hyamine 3500J manufactured by Lonza Japan Co., Ltd. (a mixture containing one alkyl group having 8 to 18 carbon atoms and one ammonium group, which is an ionic hydrophilic group)

[0056] <Amphoteric surfactant> Sodium laurylaminopropionate: Taipol Soft LAP-10 manufactured by Taiko Yushi Kagaku Kogyo Co., Ltd. (Contains one alkyl group with 12 carbon atoms, one amine group which can also be a cationic group, and one carboxylic acid (salt) group which is an anionic group, each with a different charge. Note that, unlike betaines, depending on the liquid property, the amine group may lose its charge and may take on a form with only one ionic carboxylic acid (salt) group.) Myristyl dimethylamine oxide: Kadenax DM14D-N manufactured by Lion Specialty Chemicals Co., Ltd. (has one alkyl group with 14 carbon atoms and one amine oxide group, which is an ionic hydrophilic group.) Lauryl dimethylamine oxide: Kadenax DM12D-N manufactured by Lion Specialty Chemicals Co., Ltd. (has one alkyl group with 12 carbon atoms and one amine oxide group, which is an ionic hydrophilic group.) Decyldimethylamine oxide: GENAMINOX K10 manufactured by Clariant Japan Co., Ltd. (has one amine oxide group, which is an ionic hydrophilic group, but only one alkyl group with 10 carbon atoms) Octyldimethylamine oxide: GENAMINOXOC manufactured by Clariant Japan Co., Ltd. (has one amine oxide group, which is an ionic hydrophilic group, but only one alkyl group with 8 carbon atoms.) Coconut oil dimethylamine oxide: GENAMINOX KC manufactured by Clariant Japan Co., Ltd. (a mixture containing one alkyl group having 10 to 16 carbon atoms and one amine oxide group, which is an ionic hydrophilic group.) Coconut oil diethylamine oxide: GENAMINOX CHE manufactured by Clariant Japan Co., Ltd. (a mixture containing one alkyl group having 10 to 16 carbon atoms and one amine oxide group, which is an ionic hydrophilic group.) Coconut oil alkyl betaine: GENAGEN B1566 manufactured by Clariant Japan Co., Ltd. (a mixture containing one alkyl group having 10 to 16 carbon atoms, and one quaternary ammonium group, which is a cationic group, and one carboxylic acid (salt) group, which is an anionic group, each with different charges.) Lauryl dimethyl betaine: Amphitol 24B manufactured by Kao Corporation (has one alkyl group with 12 carbon atoms, and one quaternary ammonium group (a cationic group) and one carboxylic acid (salt) group (anionic group) with different electric charges). Stearyl dimethyl betaine: Amphitol 86B manufactured by Kao Corporation (has one alkyl group with 18 carbon atoms, and one quaternary ammonium group (a cationic group) and one carboxylic acid (salt) group (anionic group) with different electric charges). Sodium lauryldiaminoethylglycinate: Levon 15 manufactured by Sanyo Chemical Industries, Ltd. (has one alkyl group with 12 carbon atoms, and one cationic amine group and one anionic carboxylic acid (salt) group, each with different charges.)

[0057] <Nonionic surfactant> Alkyl glucoside: Plantacare 2000UP manufactured by BASF Ltd. (a mixture containing one alkyl group with 8 to 16 carbon atoms and no ionic hydrophilic group) Butyl glucoside: SIMULSOLSL4 manufactured by SEPPIC (does not contain an ionic hydrophilic group, but does not contain a hydrophobic group with 7 or more carbon atoms) Fatty acid alkanolamide, manufactured by Miyoshi Oil & Fat Co., Ltd., Amycol CDE-G (a coconut oil fatty acid diethanolamide containing a fatty acid diethanolamide with one alkyl group having 11 or more carbon atoms and no ionic hydrophilic group). Polyoxyethylene tridecyl ether: Finesurf TD-100 manufactured by Aoki Oil & Fat Industries Co., Ltd. (has one alkyl group with 13 carbon atoms and no ionic hydrophilic groups) Hexaglyceryl monolaurate: SY Glystar ML-500 manufactured by Sakamoto Pharmaceutical Co., Ltd. (has one alkyl group with 11 carbon atoms and no ionic hydrophilic group) Decaglycerol monolaurate: SY Glystar ML-750 manufactured by Sakamoto Pharmaceutical Co., Ltd. (has one alkyl group with 11 carbon atoms and no ionic hydrophilic group) Tetraglycerol monolaurate: SY Glyster ML-310 manufactured by Sakamoto Pharmaceutical Co., Ltd. (has one alkyl group with 11 carbon atoms and no ionic hydrophilic group) Decaglycerol monomyristate ester: SY Glystar MM-750 manufactured by Sakamoto Pharmaceutical Co., Ltd. (has one alkyl group with 13 carbon atoms and no ionic hydrophilic group) Decaglycerol monocaprylate: SY Glystar MCA-750 manufactured by Sakamoto Pharmaceutical Co., Ltd. (has one alkyl group with 7 carbon atoms and no ionic hydrophilic group) Diglycerol monocaprylate: SY Glystar MCA-150 manufactured by Sakamoto Pharmaceutical Co., Ltd. (has one alkyl group with 7 carbon atoms and no ionic hydrophilic group) Propylene glycol monooleate: Rikemal PO-100V (manufactured by Riken Vitamin Co., Ltd.) (has one alkenyl group with 17 carbon atoms and no ionic hydrophilic group) Polyoxyethylene polyoxypropylene lauryl ether: Noigen LP-100 manufactured by Daiichi Kogyo Seiyaku Co., Ltd. (has one alkyl group with 12 carbon atoms and no ionic hydrophilic group) Polyoxyethylene polyoxypropylene tridecyl ether: Noigen TDX-100D manufactured by Daiichi Kogyo Seiyaku Co., Ltd. (has one alkyl group with 13 carbon atoms and no ionic hydrophilic group)

[0058] <Solvent> Ethyl alcohol: Fujifilm Wako Pure Chemical Industries, Ltd., ethanol (99.5) In Tables 4 to 6, the term "appropriate amount" in the column for the blending ratio of pH adjuster indicates that the pH adjuster was blended in order to adjust the pH of the antiviral composition (25°C, undiluted solution) to the value shown in the table.

[0059] [Table 1]

[0060] [Table 2]

[0061] [Table 3]

[0062] [Table 4]

[0063] [Table 5]

[0064] [Table 6]

[0065] [Table 7]

[0066] [Table 8]

[0067] (Performance evaluation) (Antiviral effect of hard surfaces against influenza viruses) The test was conducted in accordance with ISO21702 as follows. (1) Influenza virus A (H1N1) was infected into MDCK cells, a cell line derived from canine renal tubular epithelial cells, and the cells were cultured. (2) Next, we confirmed whether the cells were infected with influenza virus by measuring the cytopathic effect (CPE). After confirming the cytopathic effect, the cultured cells were disrupted by repeated freezing and thawing. (3) The cultured cell lysate was centrifuged, and the supernatant was collected to prepare a virus solution. (4) 500 μL of the antiviral composition according to each Example and Comparative Example was spread on a 5 cm × 5 cm polyethylene terephthalate (PET) resin plate and allowed to stand in a petri dish at 25° C. for 41 hours. This was used as an antiviral-treated plate. (5) 100 μL of the virus solution was dropped onto an antiviral-treated plate, a 4 cm x 4 cm film was placed on top, and the plate was left to stand for 1 hour in an environment of 25°C and 90% RH or higher. (6) 10 mL of sterile SCDLP medium was added to stop the action of the virus and the antiviral composition, and the influenza virus was washed out of the antiviral-treated plate by pipetting several times. The solution obtained by this process was used as a virus solution of the antiviral composition with 60-minute antiviral activity. (7) The virus-treated untreated PET resin plate was left standing in a petri dish at 25°C for 41 hours. This was used as an antiviral untreated plate. (8) 100 μL of the virus solution was dropped onto an antiviral untreated plate, a 4 cm x 4 cm film was placed on top, and the plate was left to stand for 60 minutes in an environment of 25°C and 90% RH or higher. (9) 10 mL of sterile SCDLP medium was added, and the influenza virus was washed out of the antiviral untreated plate by pipetting several times. The solution obtained by this step was used as the antiviral untreated virus solution. (10) Antiviral composition 60-minute antiviral effect The virus solution and the untreated virus solution were each serially diluted 10-fold with EMEM medium containing 2 μg / mL trypsin (crystals derived from bovine spleen) (hereinafter referred to as trypsin-containing EMEM medium). The medium was discarded from a 96-well microplate in which MDCK cells had been cultured, and 100 μL of the serially diluted solution was added per well. (11) The added MDCK cells were cultured at 37°C and 5% CO2 for 1 hour. (12) After incubation, the serial dilutions were discarded, and 100 μL of trypsin-containing EMEM medium was added per well. (13) The added MDCK cells were cultured at 37°C and 5% CO2 for 4 days. (14) TCID 50 The viral infectious titer (logarithm) of each virus solution was quantified using Tissue Culture Infectious Dose 50%. (15) The steps (1) to (14) above were performed three times independently, and the average value of the virus infectivity titer calculated using the antiviral untreated virus solution was defined as the antiviral untreated virus infectivity titer, and the average value of the virus infectivity titer calculated using the antiviral composition 60-minute antiviral action virus solution was defined as the virus infectivity titer after 60 minutes of action. The reduction in infectious titer was calculated by subtracting the viral infectious titer after 60 minutes of exposure from the viral infectious titer of the untreated virus. The reduction in infectious titer in the table is expressed in common logarithms. The evaluation criteria were as follows: The results are shown in Tables 1 to 7. ◎: Reduction in infectious titer of 4.0 or more (disinfection of 99.99% or more of the virus) 〇: Reduction in infectious titer of 2.0 or more and less than 4.0 (disinfection of 99% or more and less than 99.99% of viruses) ×: Reduction in infectious titer of less than 2.0 (less than 99% of the virus is disinfected) Furthermore, if the reduction in infectious titer is 2.0 or more (evaluation is 0 or more), the antiviral effect against influenza virus is good.

[0068] (Antiviral effect of hard surfaces against human coronaviruses) (1) Human coronaviruses were infected into MRC-5 cells, which are normal human diploid fibroblasts, and the cells were cultured. (2) Next, we confirmed whether the cells were infected with human coronavirus by measuring the cytopathic effect (CPE). After confirming the cytopathic effect, the cultured cells were disrupted by repeated freezing and thawing. (3) The cultured cell lysate was centrifuged, and the supernatant was collected to prepare a virus solution. (4) 500 μL of the antiviral composition according to each Example and Comparative Example was spread on a 5 cm × 5 cm polyethylene terephthalate (PET) resin plate and allowed to stand in a petri dish at 25° C. for 168 hours. This was used as an antiviral-treated plate. (5) 100 μL of the virus solution was dropped onto an antiviral-treated plate, a 4 cm x 4 cm film was placed on top, and the plate was left to stand for 60 minutes in an environment of 25°C and 90% RH or higher. (6) 10 mL of sterile SCDLP medium was added to stop the action of the virus and the antiviral composition, and the human coronavirus was washed out of the antiviral-treated plate by pipetting several times. The solution obtained by this process was used as a virus solution containing the antiviral composition for 60 minutes of antiviral activity. (7) The virus-treated untreated PET resin plate was left standing in a petri dish at 25°C for 168 hours. This was used as an antiviral untreated plate. (8) 100 μL of the virus solution was dropped onto an antiviral untreated plate, a 4 cm x 4 cm film was placed on top, and the plate was left to stand for 60 minutes in an environment of 25°C and 90% RH or higher. (9) 10 mL of sterile SCDLP medium was added, and the human coronavirus was washed out of the antiviral untreated plate by pipetting several times. The solution obtained by this process was used as the antiviral untreated virus solution. (10) Antiviral composition 60-minute antiviral effect The virus solution and the untreated virus solution were each serially diluted 10-fold with MEM medium containing 5% FBS (fetal bovine serum). The medium was discarded from a 96-well microplate containing MRC-5 cells, and 100 μL of the serially diluted solution was added to each well. (11) MRC-5 cells containing the serially diluted solutions were cultured at 37°C in 5% CO2 for 1 hour. (12) After incubation, the serial dilutions were discarded, and 100 μL of FBS-containing MEM medium was added per well. (13) The added MRC-5 cells were cultured at 37°C and 5% CO2 for 4 days. (14) The viral infectious titer (logarithm) of each virus solution was quantified using TCID50 (Tissue Culture Infectious Dose 50%) as an indicator of CPE in cultured MRC-5 cells. (15) The steps (1) to (14) above were performed three times independently, and the average value of the virus infectivity titer calculated using the antiviral untreated virus solution was defined as the antiviral untreated virus infectivity titer, and the average value of the virus infectivity titer calculated using the antiviral composition 60-minute antiviral action virus solution was defined as the virus infectivity titer after 60 minutes of action. The reduction in infectious titer was calculated by subtracting the viral infectious titer after 60 minutes of exposure from the viral infectious titer of the untreated virus. The reduction in infectious titer in the table is expressed in common logarithms. The evaluation criteria are as follows: ◎: Reduction in infectious titer of 4.0 or more 〇: Reduction in infectious titer of 2.0 or more and less than 4.0 ×: Decrease in infectious titer of less than 2.0 Furthermore, if the reduction in infectious titer is 2.0 or more (evaluation is 0 or more), the antiviral effect against coronavirus is good.

[0069] <Virus inactivation effect> (1) Influenza virus A (H1N1) was infected into MDCK cells, a cell line derived from canine renal tubular epithelial cells, and the cells were cultured. (2) Next, we confirmed whether the cells were infected with influenza virus by measuring the cytopathic effect (CPE). After confirming the cytopathic effect, the cultured cells were disrupted by repeated freezing and thawing. (3) The cultured cell lysate was centrifuged, and the supernatant was collected to prepare a virus solution. (4) The antiviral composition according to each Example and Comparative Example was mixed with a virus solution in a 5:1 ratio (volume), left at room temperature for 1 minute, and then diluted 100-fold with EMEM medium containing 2 μg / mL trypsin (crystals derived from bovine spleen) (hereinafter referred to as trypsin-containing EMEM medium) to stop the action of each antiviral composition against the virus. The solution obtained by this step was used as a virus solution for one-minute inactivation of the antiviral composition. (5) Trypsin-containing EMEM medium and the virus solution were mixed in a 5:1 ratio (volume), and immediately thereafter the solution was diluted 100-fold with trypsin-containing EMEM medium to prepare a virus solution with 0-minute inactivation effect of the antiviral composition. (6) The virus solution of the antiviral composition with 0-minute inactivation effect and the virus solution of the antiviral composition with 1-minute inactivation effect were each serially diluted 10-fold with trypsin-containing EMEM medium. The medium was discarded from a 96-well microplate in which MDCK cells had been cultured, and 100 μL of the serially diluted solution was added per well. (7) MDCK cells to which serial dilutions of the virus solution with 0-minute inactivation effect of the antiviral composition and the virus solution with 1-minute inactivation effect of the antiviral composition had been added were cultured at 37°C and 5% CO2 for 4 days. (8) TCID using CPE of cultured MDCK cells as an indicator 50The viral infectious titer (logarithm) of each virus solution was quantified using Tissue Culture Infectious Dose 50%. (9) The steps (1) to (8) were carried out three times independently, and the average value of the virus infectivity titer calculated using the virus solution with 0-minute inactivation effect of the antiviral composition was defined as the virus infectivity titer at 0 minutes of action time, and the average value of the virus infectivity titer calculated using the virus solution with 1-minute inactivation effect of the antiviral composition was defined as the virus infectivity titer at 1 minute of action time. The evaluation criteria were as follows: The results are shown in Tables 1 to 7. ◎: Reduction in infectious titer of 4.0 or more (disinfection of 99.99% or more of the virus) 〇: Reduction in infectious titer of 2.0 or more and less than 4.0 (disinfection of 99% or more and less than 99.99% of viruses) ×: Reduction in infectious titer of less than 2.0 (less than 99% of the virus is disinfected) If the reduction in infectious titer is 2.0 or more (evaluation is 0 or more), the influenza virus inactivation effect is good.

[0070] Tables 1 to 8 reveal that the antiviral compositions according to the examples exhibit excellent antiviral effects. The antiviral compositions of Examples 1 to 20, 24 to 37, 39 to 47, 49, and 51 to 53 exhibit the above-mentioned excellent antiviral effect even without blending a lower alcohol (alcohol). Even when used on an object made of plastic such as PET, these antiviral compositions can sufficiently prevent the object from deteriorating. The antiviral compositions of the Examples can also be used on other objects, and can impart antiviral properties while sufficiently preventing the object from deteriorating. The antiviral compositions according to the examples exhibit a certain antiviral effect even when the surfactant concentration is very low (for example, 0.008% by mass as shown in Example 38, and 0.014% by mass as shown in Example 39). Furthermore, the antiviral compositions according to the examples exhibit excellent antiviral effect even when the surfactant concentration is low (for example, 0.1% by mass as shown in Examples 8 and 10). Furthermore, the antiviral compositions of Examples 21 to 23 further differ from the antiviral compositions of Examples 1, 5, and 13 in that they contain a lower alcohol (alcohol) in place of a portion of the purified water, thereby exhibiting the above-described excellent antiviral effect and also exhibiting an extremely excellent virus inactivation effect. It is believed that such antiviral compositions can also exhibit an extremely excellent bactericidal effect. Antiviral coating agents and sanitary materials containing the antiviral compositions according to these Examples can exhibit excellent antiviral effects, can impart antiviral properties to the surfaces of various articles and the body, and can adequately prevent viral infections.

Claims

1. 1. An antiviral composition comprising a surfactant, The surfactant has no ionic hydrophilic group and at least one hydrophobic group having 7 or more carbon atoms, or has only one ionic hydrophilic group or has ionic hydrophilic groups with different charges, and at least one hydrophobic group having 11 or more carbon atoms or at least two hydrophobic groups having 9 or more carbon atoms. An antiviral composition characterized by:

2. The antiviral composition according to claim 1 , wherein the hydrophobic group is a hydrocarbon group.

3. The antiviral composition according to claim 1 or 2, which is used on a hard surface.

4. The antiviral composition according to claim 1 or 2, which is used on a plastic surface.

5. An antiviral coating agent comprising the antiviral composition according to claim 1.

6. The antiviral coating agent according to claim 5, which is used to coat human skin.

7. A sanitary material comprising the antiviral composition according to claim 1 or 2, or the antiviral coating agent according to claim 5 or 6.

Images